Oculis Holding AG Ordinary shares (OCS NASDAQ) stock market data APIs
$27.3418
0(0%)
as of May 1, 2026
Try our APIs with
free plan!
Oculis Holding AG Ordinary shares Financial Data Overview
Price chart is built with
Anychart
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Prev. Close
27.3418
Open
27.6848
High
27.9751
Low
26.8422
52 wk Range
16-30.68
Market Cap
1 593 M
Shares Outstanding
57 984 K
Revenue
1 199 K
EPS
-0.42
Beta
0.208
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oculis Holding AG Ordinary shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oculis Holding AG Ordinary shares data using free add-ons & libraries
Get Oculis Holding AG Ordinary shares Fundamental Data
Oculis Holding AG Ordinary shares Fundamental data includes:
- Net Revenue: 1 199 K
- EBITDA: -81 520 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Oculis Holding AG Ordinary shares Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-04
- EPS/Forecast: -0.4112
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oculis Holding AG Ordinary shares News
New
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kupperman...
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive t...
Oculis Completes Last Patient Visit In Phase 3 DIAMOND For OCS-01 Eye Drops In D. Macular Edema
(RTTNews) - Oculis Holding AG (OCS), a clinical-stage biopharmaceutical, announced on Monday the completion of the final patient visit in the Phase 3 DIAMOND program of OCS-01,it's lead investigationa...
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative lo...
Get Oculis Holding AG Ordinary shares fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
